Vivimed LabsNSE:VIVIMEDLAB 42 Receivables Turnover is 0.18 as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 42/100 and a GF Value™ of ₹2.55 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 947 Drug Manufacturers companies, Vivimed Labs ranks worse than 97.57% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vivimed Labs's Revenue for the
three
months ended in Dec. 2025 was ₹159.9 Mil. Vivimed Labs's average Accounts Receivable for the
three
months ended in Dec. 2025 was ₹893.4 Mil.
Hence, Vivimed Labs's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.18.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vivimed Labs Receivables Turnover Related Terms
Vivimed Labs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VIVIMEDLAB vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivimed Labs (NSE:VIVIMEDLAB) has a Receivables Turnover of 0.18 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vivimed Labs and its competitors. According to the industry distribution chart, Vivimed Labs ranks #924 out of 947 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is Vivimed Labs' Receivables Turnover too high?
Vivimed Labs' current Receivables Turnover is 0.18. The Drug Manufacturers industry median Receivables Turnover is 5.07. Vivimed Labs' value of 0.18 is 96.4% below this industry median. Based on the distribution chart, Vivimed Labs ranks #924 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivimed Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #924 out of 947 companies for Receivables Turnover. This places Vivimed Labs in the lower half of its industry. The industry median Receivables Turnover is 5.07. Vivimed Labs' value of 0.18 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivimed Labs's current Receivables Turnover of 0.18 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current Receivables Turnover is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.55, compared to a current price of ₹5.41 — trading 112.2% above its estimated fair value. The current Receivables Turnover is 0.18 and 96.4% below the Drug Manufacturers industry median of 5.07. Vivimed Labs' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Receivables Turnover is 0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹5.41 is trading 112.2% above its estimated GF Value™ of ₹2.55.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
Receivables Turnover: 0.18
GF Value™: ₹2.55 vs. price of ₹5.41 (112.2% above fair value)
Industry Position: 96.4% below the Drug Manufacturers median (#924 of 947)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
42GF Score
Get the complete analysis for NSE:VIVIMEDLAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
